Matt Thomas, Research Manager at the University of Washington, is studying host-viral pathogen responses through RNA-seq or 16S profiling by utilizing the high-throughput and simplified workflow of Illumina next-generation sequencing systems. The NextSeq 500 enables the complex research the lab performs using small RNA, and RIP seq, moving beyond just gene expression. The quick turnaround combined with the flexibility of short and long reads is a real asset to their cutting-edge work in virology. “The NextSeq 500 has become the workhorse for sequencing in the lab”, says Thomas. The majority of experiments and funding mechanisms use the NextSeq 500 to generate data.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015.
Subscribe to the Illumina video channel
View customer spotlight videos